Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

Despite improvements in standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with untreated, diffuse large B-cell lymphoma, up to 40% of these patients relapse. Lenalidomide alone or in combination with rituximab has been shown to be active in relap...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chiappella, Annalisa, Tucci, Alessandra, Castellino, Alessia, Pavone, Vincenzo, Baldi, Ileana, Carella, Angelo Michele, Orsucci, Lorella, Zanni, Manuela, Salvi, Flavia, Liberati, Anna Marina, Gaidano, Gianluca, Bottelli, Chiara, Rossini, Bernardo, Perticone, Sonia, De Masi, Pasqualina, Ladetto, Marco, Ciccone, Giovannino, Palumbo, Antonio, Rossi, Giuseppe, Vitolo, Umberto
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2013
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3815174/
https://ncbi.nlm.nih.gov/pubmed/23812930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.085134
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars